<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Stereotactic body radiation therapy for lung tumors</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Stereotactic body radiation therapy for lung tumors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Stereotactic body radiation therapy for lung tumors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Josh H Heinzerling, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert D Timmerman, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rogerio C Lilenbaum, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven E Schild, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric Vallières, MD, FRCSC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Stereotactic body radiation therapy (SBRT) is a technique that utilizes precisely targeted radiation to a tumor while minimizing radiation to adjacent normal tissue. This targeting allows treatment of small- or moderate-sized tumors in either a single or limited number of dose fractions. (See  <a class="medical medical_review" href="/d/html/89528.html" rel="external">"Radiation therapy techniques in cancer treatment"</a>.)</p><p>Stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT) initially were used successfully for intracranial, orbital, and base of skull tumors, as well as benign conditions in which the skull could be used as a reference system. (See  <a class="medical medical_review" href="/d/html/7063.html" rel="external">"Stereotactic cranial radiosurgery"</a>.)</p><p>The success of SRS for intracranial indications led to the development of techniques to extend this approach to extracranial targets. Stereotactic radiation therapy for extracranial sites has required significant technical advances including tumor imaging to guide radiation administration, patient immobilization, and conformal radiation delivery techniques.</p><p>SBRT has been defined by the American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) as the use of very large doses of radiation, defined as &gt;6 Gy/fraction given over few (five or fewer) fractions [<a href="#rid1">1</a>]. SBRT has unique radiobiologic characteristics, which can cause dramatic tumor response, leading to the associated term "ablative" radiotherapy.</p><p>The rationale for SBRT in treating both primary non-small cell lung cancer (NSCLC) and metastatic lung tumors, specific techniques, and early results with this technique will be reviewed here.</p><p class="headingAnchor" id="H2"><span class="h1">TECHNIQUES FOR LUNG TUMORS</span><span class="headingEndMark"> — </span>The proximity of lung tumors to critical thoracic structures requires that the high doses of oligofractionated radiation therapy used in SBRT be delivered accurately and precisely to minimize normal tissue exposure to radiation. SBRT thus requires reliable and reproducible patient immobilization, daily imaging for accurate repositioning from simulation to treatment, use of multiple treatment fields, and a method of accounting for tumor and organ motion during treatment.</p><p class="headingAnchor" id="H3"><span class="h2">Patient positioning and immobilization</span><span class="headingEndMark"> — </span>Consistent, reproducible, and comfortable patient immobilization is essential for ensuring treatment accuracy.</p><p>There are several commercially available systems designed for stereotactic patient positioning and immobilization, including body frames, vacuum cushions, and thermal plastic restraints. These devices typically feature a stereotactic fiducial system that is rigidly attached and registered to the target. Other, so called "frameless" systems rely on methods to effectively relocate a reference position within the patient. As an example, implanted fiducial seeds within the tumor can be accurately relocated on a daily basis using imaging techniques. Newer technologies under development include magnetic resonance imaging (MRI) or positron emission tomography (PET) imaging that can identify targets that can be tracked in real time to ensure accurate positioning during the entire treatment course.</p><p class="headingAnchor" id="H4"><span class="h2">Image-guided treatment</span><span class="headingEndMark"> — </span>Sophisticated image guidance, typically with computed tomography (CT) and more recently with MRI or PET, is incorporated into the treatment unit and allows validation of patient positioning prior to each treatment. Image-guided radiation therapy minimizes the uncertainty associated with external reference points and allows accurate tumor localization in near real time. Because lung tumors are very distinct on CT scan, pretreatment reference volumes can be linked to the image and appropriate adjustments can be reliably made on the day of treatment.</p><p class="headingAnchor" id="H5"><span class="h2">Tumor motion control</span><span class="headingEndMark"> — </span>Lung tumors often move relative to other thoracic structures particularly during the respiratory cycle. This motion can vary significantly depending upon the location of the tumor and patient characteristics [<a href="#rid2">2,3</a>].</p><p>Several methods exist to reduce or compensate for tumor motion [<a href="#rid4">4-10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal compression places a pressure device on the abdomen to reduce motion related to the diaphragm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Deep inspiration and breath holding attempts to arrest the tumor in a reproducible position within the respiratory cycle.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory gating combines these approaches to trigger delivery of radiation during a specific segment of the respiratory cycle.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumor tracking systems actually move the radiation beam to follow the motion of the tumor.</p><p></p><p>Regardless of the method used, careful assurance of accuracy, reproducibility, as well as implementation of motion data into treatment planning, is essential for precise treatment delivery with SBRT.</p><p class="headingAnchor" id="H6"><span class="h2">Treatment planning</span><span class="headingEndMark"> — </span>SBRT utilizes advanced treatment planning approaches to minimize radiation exposure outside the planned tumor volume. This is accomplished by using multiple beams (typically 10 to 12) or large angle arc rotations. Use of nonopposing beams is encouraged to avoid overlap of dose at points of entrance and exit. In most circumstances, noncoplanar beams are preferred to further spread out the entrance and exit dose within normal tissues. Alternatively, volumetric modulated arc therapy is often used today and is an intensity modulated radiation therapy-based treatment targeting system.</p><p>Target volumes are determined using mechanisms to predict and quantify tumor motion such as four-dimensional CT and fluoroscopy. Intravenous contrast is potentially useful, even for small tumors, to differentiate tumor (intermediate density) from atelectasis (low density) and adjacent vessels (high density). When tumor is hard to differentiate from normal tissue, advanced imaging techniques such as positron emission tomography (PET) or magnetic resonance imaging (MRI) can be combined with CT to accurately determine tumor volume. As an example, in lung tumors adjacent to the chest wall or associated with lung atelectasis or consolidation, PET/CT can help delineate targets more precisely than CT images alone.</p><p>Reducing high doses of incidental radiation outside the intended treatment volume is critical to preventing normal tissue toxicity with the high-dose fractions used in SBRT. Protocols commonly define criteria related to the conformality of target dose and compactness of intermediate dose. In addition, normal tissue dose constraints are being developed and modified based on existing data from patients treated with SBRT to help predict toxicity based on dose-volume relationships.</p><p class="headingAnchor" id="H7"><span class="h1">PRIMARY NSCLC</span><span class="headingEndMark"> — </span>Surgical resection remains the standard therapy for patients with stage I non-small cell lung cancer (NSCLC) who are surgical candidates. Five-year survival rates range from approximately 60 to 70 percent. (See  <a class="medical medical_review" href="/d/html/4642.html" rel="external">"Management of stage I and stage II non-small cell lung cancer", section on 'Surgical candidates'</a>.)</p><p>However, SBRT is an alternative as primary treatment for patients who are not candidates for or who refuse surgery  (<a class="graphic graphic_diagnosticimage graphicRef120869" href="/d/graphic/120869.html" rel="external">image 1</a>). In a phase III randomized trial comparing SBRT with conventionally fractionated radiotherapy in patients who are not candidates for surgery, SBRT was associated with both improved local control for peripherally situated tumors as well overall survival at three years post-therapy [<a href="#rid11">11</a>]. The data supporting the use of SBRT in patients with stage I or II NSCLC and the data comparing SBRT with surgery are discussed separately. (See  <a class="medical medical_review" href="/d/html/4642.html" rel="external">"Management of stage I and stage II non-small cell lung cancer", section on 'Stereotactic body radiation therapy'</a>.)</p><p>For those who will be receiving SBRT for primary NSCLC, we typically administer three fractions over 1.5 to 2 weeks, using fractions of 18 Gy for peripherally situated tumors based on Radiation Therapy Oncology Group (RTOG) 0236 [<a href="#rid12">12,13</a>]. Alternatively, a single fraction of 34 Gy or four fractions of 12 Gy has been evaluated with acceptable five-year outcomes, although larger studies are needed [<a href="#rid14">14</a>].</p><p>For central tumors, 5 fractions over 2.0 to 2.5 weeks is better tolerated than a 3 fraction regimen, using fractions of 10 to 12 Gy. In a phase I/II study of patients with T1 to 2, node-negative, centrally located NSCLC, the maximum tolerated dose was 12 Gy/fraction, which was associated with dose-limiting toxicity in 7.2 percent [<a href="#rid15">15</a>]. Two-year rates of local control in the 11.5- and 12.0-Gy/fraction cohorts were 89 and 88 percent, respectively. Most United States centers continue to use 5 fractions of 10 Gy for central tumors to avoid high grade toxicity in a frail population. More protracted treatments or treatments with longer intervals between fractions are being studied to avoid toxicity for central tumors [<a href="#rid16">16</a>].</p><p>An early phase II randomized trial comparing SBRT alone with combining SBRT and immunotherapy suggests improved event-free survival at four years with the addition of immunotherapy in the treatment of stages IA to IB patients with who were unable or unwilling to undergo surgical resection [<a href="#rid17">17</a>]. Further data are needed prior to routine use of this strategy. (See  <a class="medical medical_review" href="/d/html/4642.html" rel="external">"Management of stage I and stage II non-small cell lung cancer", section on 'Stereotactic body radiation therapy'</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">LUNG METASTASES</span><span class="headingEndMark"> — </span>The lungs are one of the most common sites of spread of disease for patients with a wide variety of primary tumors. Although this usually is a manifestation of widespread disease, carefully selected patients benefit from surgical resection of one or a limited number of lung metastases when this is the sole site of recurrence. (See  <a class="medical medical_review" href="/d/html/7815.html" rel="external">"Surgical resection of pulmonary metastases: Benefits, indications, preoperative evaluation, and techniques"</a>.)</p><p>SBRT appears to be an effective and well tolerated local therapy for patients with limited metastatic disease within the lung. Local control rates in patients with lung metastases have ranged from 67 to 92 percent using various dose fractionation schemes [<a href="#rid18">18-23</a>]. These results suggest that SBRT provides equivalent local control to surgical resection; thus, SBRT may be an alternative to surgery in patients with oligometastatic disease.</p><p>The potential role of SBRT in patients with lung metastases is illustrated in the trials below:</p><p class="bulletIndent1"><span class="glyph">●</span>In a single-institution series of 121 patients with five or fewer lung metastases, the two-year and four-year local control rates following SBRT were 77 and 73 percent, respectively [<a href="#rid19">19</a>]. A subsequent report based upon the same series observed that SBRT was used to retreat nine recurrent and 29 new lung lesions, which developed after the initial SBRT treatment [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a multicenter phase I/II study of 38 patients, each with one to three enlarging pulmonary metastases, the SBRT dose was escalated from 48 to 60 Gy given divided into three fractions [<a href="#rid18">18</a>]. None of the 12 patients in the phase I portion of the study experienced a dose-limiting toxicity. In an analysis of the assessable 50 lesions, actuarial local control rates at one and two years were 100 and 96 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subsequent trials including patients receiving SBRT to various sites including the lung have also shown conflicting results. One trial in 99 patients demonstrated improvements in median overall survival with SBRT to metastatic sites (HR 0.47, 95% CI 0.27-0.81) [<a href="#rid24">24</a>]. Approximately half of the metastatic lesions were in the lungs, and the majority of patients had one to three metastases. By contrast, a separate randomized phase II trial failed to demonstrate benefit from adding stereotactic radiotherapy to a limited number of metastatic lesions in patients receiving immune checkpoint inhibitors as monotherapy [<a href="#rid25">25</a>]. Approximately one-third of patients in this trial were treated for lesions in the lungs.</p><p></p><p class="headingAnchor" id="H604603502"><span class="h1">REIRRADIATION</span><span class="headingEndMark"> — </span>Because of the conformal high doses given with SBRT, its use has extended to patients previously treated with thoracic radiation.</p><p>Multiple series and one small prospective trial have looked at using SBRT in the setting of local failure after prior fractionated radiation for early-stage or locally advanced non-small cell lung cancer. Doses used have included 48 Gy in four fractions [<a href="#rid26">26</a>] as well as dose ranges over 5 to 10 fractions [<a href="#rid26">26-32</a>]. Reported local control rates have been encouraging, ranging from 60 to 95 percent, but levels of toxicity have also been higher than SBRT in previously untreated tumors, including higher percentage of fatal radiation-induced toxicities [<a href="#rid30">30</a>]. The increased risk of toxicity suggests that caution should be taken in selection and therapy of these patients to avoid significant late toxicity.</p><p class="headingAnchor" id="H604603509"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>Typically, follow-up computed tomography (CT) scans of the chest with contrast are the preferred method of following both primary and metastatic lesions treated with SBRT. Follow-up CT scans are generally performed at intervals of three to six months, as was suggested in the clinical trial setting. Because of the inflammation and fibrosis caused by hypofractionated radiation, changes seen on CT can often mimic disease progression and can be difficult to distinguish from radiation injury.</p><p>Careful communication with thoracic radiologists including knowledge of the dosimetry and potential effects of high-dose radiation is essential. Certain patterns of response to SBRT and subsequent CT changes correlating with radiation fibrosis are well described in the literature and can be used as guides when interpreting follow-up scans [<a href="#rid33">33,34</a>].</p><p>When there is a suggestion of progressive disease after SBRT, correlation with other imaging modalities, such as positron emission tomography (PET)/CT, is warranted and biopsy confirmation of relapse is recommended if feasible [<a href="#rid35">35,36</a>]. Because moderate residual metabolic uptake can often be seen up to 12 months after SBRT [<a href="#rid37">37</a>], PET/CT in the absence of suspicious CT changes is not routinely recommended.</p><p class="headingAnchor" id="H11"><span class="h1">TOXICITY</span><span class="headingEndMark"> — </span>Because of the high doses per fraction used during SBRT, there is an increased risk of normal tissue toxicity compared with conventionally fractionated radiation therapy unless care is taken to minimize radiation exposure to normal structures. The numbers of patients and length of follow-up are limited in the studies described above. However, prospective assessment of dosimetric endpoints such as dose volume information has been used to modify SBRT dose constraints in normal tissues, and SBRT for thoracic lesions appears to have a reasonable safety profile.</p><p>The Radiation Therapy Oncology Group (RTOG) has observed reasonable rates of toxicity for treatment of medically inoperable patients when the SBRT dose is divided into three fractions for peripheral tumors [<a href="#rid12">12</a>]. Grade 3 to 4 toxicity was seen in 17 patients (31 percent) treated on RTOG 0236, and no treatment-related deaths were seen with five years of follow-up [<a href="#rid13">13</a>]. Additionally, in a meta-analysis evaluating 21 prospective studies of patients receiving SBRT to various sites (29 percent of whom received SBRT to the lung), the estimated rates of acute and late grade ≥3 effects were 1.2 and 1.7 percent, respectively [<a href="#rid38">38</a>]. Other studies have also observed that SBRT was well tolerated, and that changes in pulmonary function tests were minimal [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H447863826"><span class="h2">Peripheral and apical lesions</span><span class="headingEndMark"> — </span>For lesions near the lung periphery, chest wall toxicity may be manifested by rib fractures or pain [<a href="#rid40">40-42</a>]. The incidence of chest wall toxicity was illustrated by a series of 347 treated lesions, which included 203 on the chest wall. Both chest wall pain and rib fractures were more frequent when chest wall lesions were irradiated compared with nonchest wall lesions (16 versus 3 percent and 8 versus 1 percent, respectively) [<a href="#rid42">42</a>].</p><p>When SBRT is used to treat primary lung cancers in apical sites, there may be an increased risk of injury to the brachial plexus. In a series of 36 patients with apical lesions treated with SBRT to a median dose of 57 Gy in three fractions, seven patients developed grade 2, 3, or 4 brachial plexopathy [<a href="#rid43">43</a>]. These authors felt that the tolerance of the major trunks of the brachial plexus was around 26 Gy for a three-fraction regimen. (See  <a class="medical medical_review" href="/d/html/5266.html" rel="external">"Brachial plexus syndromes", section on 'Neoplastic and radiation-induced brachial plexopathy'</a>.)</p><p class="headingAnchor" id="H447863780"><span class="h2">Proximal lesions</span><span class="headingEndMark"> — </span>SBRT appears to offer a reasonable alternative for patients with proximal lesions, although its safety may require some modification of the SBRT fractionation schedule.</p><p>The phase II study, which included 70 patients with medically inoperable central lung cancers, found that central and perihilar structures within the lung are very sensitive to the high doses of radiation delivered during SBRT [<a href="#rid44">44</a>]. Low-grade toxicities included fatigue, musculoskeletal pain, and radiation pneumonitis. Fourteen patients had severe toxicity, including decline in pulmonary function tests, pleural effusions, and pneumonias. There were six deaths that may have been treatment-related, the majority of which were from pneumonia. Four of the six deaths were in patients with central tumors within 2 cm from the proximal bronchial tree, and these patients had an 11-fold increased risk of having a severe toxicity compared with patients with peripheral lesions.</p><p>A systematic review of the literature, based primarily upon retrospective case series, included data from 315 patients with central early-stage non-small cell lung cancer in 20 studies [<a href="#rid45">45</a>]. This review concluded that local control could be achieved as effectively as with peripheral lesions, with an acceptable level of toxicity, provided that an adequate dose of radiation to the periphery of the tumor was maintained. However, a Scandinavian study including "ultra" central tumors only 1 cm from the central bronchial tree demonstrated high grade toxicity in 22 of 65 patients including 10 toxic deaths after 8 fractions of 7 Gy [<a href="#rid46">46</a>]. While this experience shows higher toxicity than most reports, care must be taken in treating proximal lesions.</p><p class="headingAnchor" id="H447863773"><span class="h2">Lung metastases</span><span class="headingEndMark"> — </span>When SBRT is used to treat patients with lung metastases, toxicity is typically less severe than that for those with primary lung cancer. These patients tend to present with better overall lung function and are more likely to have peripherally located tumors. In the multicenter dose-escalation study, no grade 4 to 5 toxicity was seen, and there were no treatment-related deaths [<a href="#rid18">18</a>]. Although multiple patients had more than one lesion treated with SBRT, only three had grade 3 toxicity. However, in the randomized trial described above, two treatment-related deaths were observed among patients receiving SBRT to lung metastases [<a href="#rid47">47</a>]. (See <a class="local">'Lung metastases'</a> above.)</p><p class="headingAnchor" id="H4177121177"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112231.html" rel="external">"Society guideline links: Diagnosis and management of lung cancer"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">SUMMARY AND RECOMMENDATIONS</span><span class="headingEndMark"> — </span>Stereotactic body radiation therapy (SBRT) is a radiation therapy technique that utilizes precisely targeted radiation to a tumor while minimizing radiation to adjacent normal tissue. This targeting allows treatment of small- or moderate-sized tumors in either a single or limited number of dose fractions. (See <a class="local">'Techniques for lung tumors'</a> above.)</p><p>Application of SBRT techniques in patients with small primary non-small cell lung cancers (NSCLCs) or lung metastases has given results similar to surgical resection, although long-term follow-up data are not available. There are no results from randomized clinical trials comparing SBRT with surgery or other ablative techniques such as radiofrequency ablation. (See  <a class="medical medical_review" href="/d/html/4624.html" rel="external">"Image-guided ablation of lung tumors"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Primary NSCLC</span></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with adequate pulmonary function and without serious medical comorbidity, we recommend surgical resection as the initial treatment for patients with stage I or II non-small cell lung cancer (NSCLC) rather than radiation therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See  <a class="medical medical_review" href="/d/html/4642.html" rel="external">"Management of stage I and stage II non-small cell lung cancer", section on 'Surgical candidates'</a> and <a class="local">'Primary NSCLC'</a> above and  <a class="medical medical_review" href="/d/html/4624.html" rel="external">"Image-guided ablation of lung tumors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with primary tumors smaller than 7 cm and impaired pulmonary function or medical comorbidity that precludes surgical resection, we suggest SBRT rather than conventionally fractionated radiation therapy, if appropriate technical expertise is available (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Primary NSCLC'</a> above and  <a class="medical medical_review" href="/d/html/4624.html" rel="external">"Image-guided ablation of lung tumors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with larger primary tumors and impaired pulmonary function or medical comorbidity that precludes surgical resection, we recommend definitive standard-fractionation radiation therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>) (see  <a class="medical medical_review" href="/d/html/4642.html" rel="external">"Management of stage I and stage II non-small cell lung cancer", section on 'Nonsurgical candidates'</a>). To date, there are no randomized studies that compare SBRT versus radiofrequency ablation in these patients. (See  <a class="medical medical_review" href="/d/html/4624.html" rel="external">"Image-guided ablation of lung tumors"</a>.)</p><p></p><p class="headingAnchor" id="H14"><span class="h2">Lung metastases</span></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with a limited number of lung metastases who meet the criteria for resection, SBRT may be an appropriate alternative to surgery, particularly in those with significant medical comorbidity. SBRT offers a survival benefit relative to surgery. (See  <a class="medical medical_review" href="/d/html/7815.html" rel="external">"Surgical resection of pulmonary metastases: Benefits, indications, preoperative evaluation, and techniques", section on 'Criteria for considering a resection'</a> and <a class="local">'Lung metastases'</a> above and  <a class="medical medical_review" href="/d/html/4624.html" rel="external">"Image-guided ablation of lung tumors"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Potters L, Kavanagh B, Galvin JM, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010; 76:326.</a></li><li><a class="nounderline abstract_t">Heinzerling JH, Anderson JF, Papiez L, et al. Four-dimensional computed tomography scan analysis of tumor and organ motion at varying levels of abdominal compression during stereotactic treatment of lung and liver. Int J Radiat Oncol Biol Phys 2008; 70:1571.</a></li><li><a class="nounderline abstract_t">Liu HH, Balter P, Tutt T, et al. Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys 2007; 68:531.</a></li><li><a class="nounderline abstract_t">Lax I, Blomgren H, Näslund I, Svanström R. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 1994; 33:677.</a></li><li><a class="nounderline abstract_t">Negoro Y, Nagata Y, Aoki T, et al. The effectiveness of an immobilization device in conformal radiotherapy for lung tumor: reduction of respiratory tumor movement and evaluation of the daily setup accuracy. Int J Radiat Oncol Biol Phys 2001; 50:889.</a></li><li><a class="nounderline abstract_t">Wulf J, Hädinger U, Oppitz U, et al. Stereotactic radiotherapy of extracranial targets: CT-simulation and accuracy of treatment in the stereotactic body frame. Radiother Oncol 2000; 57:225.</a></li><li><a class="nounderline abstract_t">Kimura T, Hirokawa Y, Murakami Y, et al. Reproducibility of organ position using voluntary breath-hold method with spirometer for extracranial stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 2004; 60:1307.</a></li><li><a class="nounderline abstract_t">Wang LT, Solberg TD, Medin PM, Boone R. Infrared patient positioning for stereotactic radiosurgery of extracranial tumors. Comput Biol Med 2001; 31:101.</a></li><li><a class="nounderline abstract_t">Sharp GC, Jiang SB, Shimizu S, Shirato H. Prediction of respiratory tumour motion for real-time image-guided radiotherapy. Phys Med Biol 2004; 49:425.</a></li><li><a class="nounderline abstract_t">Schweikard A, Shiomi H, Adler J. Respiration tracking in radiosurgery. Med Phys 2004; 31:2738.</a></li><li><a class="nounderline abstract_t">Ball D, Mai GT, Vinod S, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol 2019; 20:494.</a></li><li><a class="nounderline abstract_t">Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303:1070.</a></li><li><a class="nounderline abstract_t">Timmerman RD, Hu C, Michalski JM, et al. Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer. JAMA Oncol 2018; 4:1287.</a></li><li><a class="nounderline abstract_t">Videtic GM, Paulus R, Singh AK, et al. Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2019; 103:1077.</a></li><li><a class="nounderline abstract_t">Bezjak A, Paulus R, Gaspar LE, et al. Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial. J Clin Oncol 2019; 37:1316.</a></li><li><a class="nounderline abstract_t">Morris Z, Dohopolski M, Rahimi A, Timmerman R. Future Directions in the Use of SAbR for the Treatment of Oligometastatic Cancers. Semin Radiat Oncol 2021; 31:253.</a></li><li><a class="nounderline abstract_t">Chang JY, Lin SH, Dong W, et al. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet 2023; 402:871.</a></li><li><a class="nounderline abstract_t">Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 2009; 27:1579.</a></li><li><a class="nounderline abstract_t">Milano MT, Katz AW, Schell MC, et al. Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2008; 72:1516.</a></li><li><a class="nounderline abstract_t">Milano MT, Philip A, Okunieff P. Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses. Int J Radiat Oncol Biol Phys 2009; 73:832.</a></li><li><a class="nounderline abstract_t">Hof H, Hoess A, Oetzel D, et al. Stereotactic single-dose radiotherapy of lung metastases. Strahlenther Onkol 2007; 183:673.</a></li><li><a class="nounderline abstract_t">Hara R, Itami J, Kondo T, et al. Stereotactic single high dose irradiation of lung tumors under respiratory gating. Radiother Oncol 2002; 63:159.</a></li><li><a class="nounderline abstract_t">Hoyer M, Roed H, Traberg Hansen A, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 2006; 45:823.</a></li><li><a class="nounderline abstract_t">Palma DA, Olson R, Harrow S, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol 2020; 38:2830.</a></li><li><a class="nounderline abstract_t">Spaas M, Sundahl N, Kruse V, et al. Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial. JAMA Oncol 2023; 9:1205.</a></li><li><a class="nounderline abstract_t">Kelly P, Balter PA, Rebueno N, et al. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys 2010; 78:1387.</a></li><li><a class="nounderline abstract_t">Kilburn JM, Kuremsky JG, Blackstock AW, et al. Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment. Radiother Oncol 2014; 110:505.</a></li><li><a class="nounderline abstract_t">Parks J, Kloecker G, Woo S, Dunlap NE. Stereotactic Body Radiation Therapy as Salvage for Intrathoracic Recurrence in Patients With Previously Irradiated Locally Advanced Non-Small Cell Lung Cancer. Am J Clin Oncol 2016; 39:147.</a></li><li><a class="nounderline abstract_t">Reyngold M, Wu AJ, McLane A, et al. Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT). Radiat Oncol 2013; 8:99.</a></li><li><a class="nounderline abstract_t">De Bari B, Filippi AR, Mazzola R, et al. Available evidence on re-irradiation with stereotactic ablative radiotherapy following high-dose previous thoracic radiotherapy for lung malignancies. Cancer Treat Rev 2015; 41:511.</a></li><li><a class="nounderline abstract_t">Owen D, Olivier KR, Song L, et al. Safety and Tolerability of SBRT after High-Dose External Beam Radiation to the Lung. Front Oncol 2014; 4:376.</a></li><li><a class="nounderline abstract_t">Trovo M, Minatel E, Durofil E, et al. Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2014; 88:1114.</a></li><li><a class="nounderline abstract_t">Shultz DB, Trakul N, Abelson JA, et al. Imaging features associated with disease progression after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer. Clin Lung Cancer 2014; 15:294.</a></li><li><a class="nounderline abstract_t">Kimura T, Matsuura K, Murakami Y, et al. CT appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: are patients with pulmonary emphysema also candidates for SBRT for lung cancers? Int J Radiat Oncol Biol Phys 2006; 66:483.</a></li><li><a class="nounderline abstract_t">Dunlap NE, Yang W, McIntosh A, et al. Computed tomography-based anatomic assessment overestimates local tumor recurrence in patients with mass-like consolidation after stereotactic body radiotherapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2012; 84:1071.</a></li><li><a class="nounderline abstract_t">Zhang X, Liu H, Balter P, et al. Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2012; 83:1558.</a></li><li><a class="nounderline abstract_t">Henderson MA, Hoopes DJ, Fletcher JW, et al. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010; 76:789.</a></li><li><a class="nounderline abstract_t">Lehrer EJ, Singh R, Wang M, et al. Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer: A Systematic Review and Meta-analysis. JAMA Oncol 2021; 7:92.</a></li><li><a class="nounderline abstract_t">Stephans KL, Djemil T, Reddy CA, et al. Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients. J Thorac Oncol 2009; 4:838.</a></li><li><a class="nounderline abstract_t">Voroney JP, Hope A, Dahele MR, et al. Chest wall pain and rib fracture after stereotactic radiotherapy for peripheral non-small cell lung cancer. J Thorac Oncol 2009; 4:1035.</a></li><li><a class="nounderline abstract_t">Dunlap NE, Cai J, Biedermann GB, et al. Chest wall volume receiving &gt;30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010; 76:796.</a></li><li><a class="nounderline abstract_t">Andolino DL, Forquer JA, Henderson MA, et al. Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver. Int J Radiat Oncol Biol Phys 2011; 80:692.</a></li><li><a class="nounderline abstract_t">Forquer JA, Fakiris AJ, Timmerman RD, et al. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother Oncol 2009; 93:408.</a></li><li><a class="nounderline abstract_t">Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006; 24:4833.</a></li><li><a class="nounderline abstract_t">Senthi S, Haasbeek CJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiother Oncol 2013; 106:276.</a></li><li><a class="nounderline abstract_t">Lindberg K, Grozman V, Karlsson K, et al. The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy. J Thorac Oncol 2021; 16:1200.</a></li><li><a class="nounderline abstract_t">Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 2019; 393:2051.</a></li></ol></div><div id="topicVersionRevision">Topic 4617 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20117285" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18374231" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Four-dimensional computed tomography scan analysis of tumor and organ motion at varying levels of abdominal compression during stereotactic treatment of lung and liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17398035" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7946448" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11429216" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The effectiveness of an immobilization device in conformal radiotherapy for lung tumor: reduction of respiratory tumor movement and evaluation of the daily setup accuracy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11054527" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Stereotactic radiotherapy of extracranial targets: CT-simulation and accuracy of treatment in the stereotactic body frame.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15519804" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Reproducibility of organ position using voluntary breath-hold method with spirometer for extracranial stereotactic radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11165218" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Infrared patient positioning for stereotactic radiosurgery of extracranial tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15012011" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prediction of respiratory tumour motion for real-time image-guided radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15543778" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Respiration tracking in radiosurgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30770291" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20233825" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Stereotactic body radiation therapy for inoperable early stage lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29852036" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30513377" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30943123" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34090653" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Future Directions in the Use of SAbR for the Treatment of Oligometastatic Cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37478883" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19255320" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18495378" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18760543" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18040611" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Stereotactic single-dose radiotherapy of lung metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12063005" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Stereotactic single high dose irradiation of lung tumors under respiratory gating.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16982546" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Phase II study on stereotactic body radiotherapy of colorectal metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32484754" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37410476" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20381271" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24444530" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24457534" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Stereotactic Body Radiation Therapy as Salvage for Intrathoracic Recurrence in Patients With Previously Irradiated Locally Advanced Non-Small Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23617949" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25913714" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Available evidence on re-irradiation with stereotactic ablative radiotherapy following high-dose previous thoracic radiotherapy for lung malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25642416" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Safety and Tolerability of SBRT after High-Dose External Beam Radiation to the Lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24661664" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24594400" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Imaging features associated with disease progression after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16904838" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : CT appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: are patients with pulmonary emphysema also candidates for SBRT for lung cancers?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22898383" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Computed tomography-based anatomic assessment overestimates local tumor recurrence in patients with mass-like consolidation after stereotactic body radiotherapy for early-stage non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22572078" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19473777" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33237270" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19487961" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19633478" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Chest wall pain and rib fracture after stereotactic radiotherapy for peripheral non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19427740" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Chest wall volume receiving&gt;30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21288656" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19454366" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17050868" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23462705" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33823286" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30982687" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
